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Sensitization of renal carcinoma 
cells to TRAIL-induced apoptosis by 
rocaglamide and analogs
Ancy D. Nalli1, Lauren E. Brown2, Cheryl L. Thomas1, Thomas J. Sayers3,4, John A. Porco Jr.2 & 
Curtis J. Henrich1,4
Rocaglamide has been reported to sensitize several cell types to TRAIL-induced apoptosis. In recent 
years, advances in synthetic techniques have led to generation of novel rocaglamide analogs. However, 
these have not been extensively analyzed as TRAIL sensitizers, particularly in TRAIL-resistant renal 
cell carcinoma cells. Evaluation of rocaglamide and analogs identified 29 compounds that are able to 
sensitize TRAIL-resistant ACHN cells to TRAIL-induced, caspase-dependent apoptosis with sub-µM 
potency which correlated with their potency as protein synthesis inhibitors and with loss of cFLIP 
protein in the same cells. Rocaglamide alone induced cell cycle arrest, but not apoptosis. Rocaglates 
averaged 4–5-fold higher potency as TRAIL sensitizers than as protein synthesis inhibitors suggesting 
a potential window for maximizing TRAIL sensitization while minimizing effects of general protein 
synthesis inhibition. A wide range of other rocaglate effects (e.g. on JNK or RAF-MEK-ERK signaling, 
death receptor levels, ROS, ER stress, eIF4E phosphorylation) were assessed, but did not contribute to 
TRAIL sensitization. Other than a rapid loss of MCL-1, rocaglates had minimal effects on mitochondrial 
apoptotic pathway proteins. The identification of structurally diverse/mechanistically similar TRAIL 
sensitizing rocaglates provides insights into both rocaglate structure and function and potential further 
development for use in RCC-directed combination therapy.
Induction of cancer cell-specific apoptosis via activation of tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) signaling has been an attractive goal for cancer therapeutics. TRAIL-induced apoptosis is initi-
ated by binding to pro-apoptotic death receptors DR4 and DR5 leading to activation of the extrinsic apoptotic 
pathway1–6 via recruitment and cleavage/activation of pro-caspase 8 in the death-inducing signaling complex 
(DISC). Activated caspase 8 is released from the DISC and in turn converts pro-caspase 3 to its active form ulti-
mately leading to apoptotic cell death. However, many tumor cells develop resistance to TRAIL-induced apop-
tosis. Among the most common mechanisms of TRAIL resistance are down-regulation of TRAIL receptors and 
overexpression of FLICE-inhibitory protein (cFLIP) which competes for binding of procaspase 8 thus blocking 
its activation5,6. Given the relatively common occurrence of TRAIL resistance in many types of cancer as well as 
non-apoptotic effects of TRAIL4, the search for enhancers of TRAIL-induced cell killing has accelerated over the 
past several years. Death receptor agonists alone or in combination with other agents (including sensitizers) have 
been used in clinical trials for cancers such as renal cell carcinoma (RCC)7,8. Kidney cancer, about 90% of which 
is RCC, is one of the most common cancer types in the United States and its incidence is increasing (https://www.
cancer.org/cancer/kidney-cancer/about.html). However, RCCs display broad resistance against conventional 
therapies9 suggesting a continued need for new therapies. TRAIL initially appeared to be a promising therapeu-
tic approach, but RCCs rapidly develop resistance to TRAIL alone. The proteasome inhibitor bortezomib has 
been used to sensitize RCC cells to TRAIL, but its use may be limited by toxicity10. The therapeutic opportunity 
for application of TRAIL and TRAIL sensitizers in RCC thus remains attractive. A high-throughput screening 
(HTS) assay was developed and identified a number of natural product enhancers of TRAIL-induced apoptosis 
in TRAIL-resistant RCC cells11–15. Among the natural products found in the HTS campaign was the protein 
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synthesis inhibitor rocaglamide (ROC) (NSC326408). Protein synthesis inhibitors, including ROC, have previ-
ously been identified as able to sensitize various cancer cell lines to TRAIL-induced apoptosis, generally assumed 
to be due to loss of cFLIP16–20.
ROC is a cyclopenta[b]benzofuran secondary metabolite isolated from the genus Aglaia, with potent anti-
proliferative, antiviral, antifungal, and anti-inflammatory properties. Structures and biological activities of ROC 
and analogs (rocaglates) have been the subject of several recent reviews21–25. Natural and synthetic rocaglates 
have been reported to have anticancer activities in vitro in various human cancer cell lines and in vivo in mouse 
models. The mechanism of action involved in the anticancer effects of ROC is generally thought to be through 
inhibition of translation initiation. However, several other cancer-related cellular effects including altered cell 
cycle progression, RAF-MEK-ERK and p38/JNK signaling, death receptor upregulation, ER stress, generation 
of reactive oxygen species (ROS), and activation of the intrinsic (mitochondrial) apoptotic pathway have been 
reported for ROC in various cancer cell types. Many of these cellular effects reported for ROC and analogs have 
also been demonstrated to sensitize cells to TRAIL-induced apoptosis1–6. Due in part to the potential of rocaglates 
as possible therapeutics for cancer and other diseases, new chemical synthesis methods have been developed and 
a large number of synthetic rocaglates have been designed for basic studies and pre-clinical development24–32. 
Although advances in synthesis have led to production of both natural rocaglates and novel rocaglamide analogs, 
few, if any, of these compounds have been investigated for activity as TRAIL sensitizers and neither ROC nor its 
analogs have been widely assessed in the context of RCC cells.
In order to further investigate the activities and potential for development of rocaglates as TRAIL sensitiz-
ers, ROC and 55 natural and synthetic analogs were assessed for their ability to sensitize the well-characterized 
TRAIL-resistant ACHN RCC cell line to TRAIL-induced apoptosis in parallel with analysis of their protein syn-
thesis inhibitory activity in the same cells under the same conditions. Other previously reported rocaglate effects 
that are relevant to TRAIL signaling and apoptosis induction were also assessed.
Results
Rocaglates sensitize ACHN cells to TRAIL. ROC and analogs (see Supplemental Table S1 for struc-
tures) were assessed for their ability to sensitize cells to TRAIL using a previously described assay11. The effects 
of ROC on ACHN cells are shown in Fig. 1. The IC50 calculated from repeated dose-response curves for ROC 
was 28.5 ± 7.5 nM (ave ± sd, n = 15 independent experiments one of which is shown in Fig. 1A). In order to 
confirm that ROC induced TRAIL-dependent apoptotic signaling, cells were assessed for activation of caspases. 
Figure 1B demonstrates sequential activation of caspase 8 (death receptor initiator caspase) followed by activa-
tion of caspase 3 (effector caspase). Caspase 8 activation in cells pre-treated with ROC was obvious at 2 h after 
addition of TRAIL and peaked at 4 h whereas caspase 3 activation was maximal ~12 h after addition of TRAIL. 
The timing of TRAIL-dependent caspase activation was consistent with previous observations with a variety of 
other TRAIL-sensitizing compounds assessed in ACHN cells11–13. Inhibition of caspase activity with ZVAD-FMK 
eliminated sensitization of the cells to TRAIL-induced apoptosis (Fig. 1C). Taken together, these observations 
reflect enhanced TRAIL-dependent apoptotic death receptor signaling. In addition to ROC, 28 other rocaglates 
significantly sensitized these cells to TRAIL – defined as IC50 < 1 µM for growth inhibition in the presence of 
TRAIL (see Supplementary Fig. S1 for dose-response curves for individual rocaglates). The structures of the 
four most potent TRAIL sensitizers (the only ones with IC50 values of <10 nM) along with ROC are shown in 
Fig. 2. These compounds were also assessed for induction of caspase activity. As with ROC, pre-treatment of cells 
with these compounds resulted in TRAIL-induced caspase activation and inhibition of sensitization to TRAIL-
induced apoptosis by the caspase inhibitor ZVAD-FMK was observed (Supplementary Fig. S2). Although ROC 
and other rocaglates as single agents resulted in growth inhibition/cytostasis, they did not significantly induce 
caspase activation (Fig. 1B), even up to 72 h treatment (Supplementary Fig. S2C) nor were their effects as single 
agents affected by Z-VAD-FMK (Figs 1C and S2B).
TRAIL sensitization by rocaglates correlates with protein synthesis inhibition and loss of cFLIP 
protein. The rocaglates were assessed for their ability to inhibit protein synthesis in ACHN cells by quantita-
tion of incorporation of puromycin into newly synthesized protein after treatment with compounds20. Figure 3A 
shows the dose-dependent inhibition of protein synthesis by ROC. There was no significant difference between 
effects after 4 h vs. 24 h treatment. Protein synthesis inhibition by the remaining rocaglates was measured after 4 h 
incubation. IC50 values for protein synthesis inhibition and for TRAIL sensitization for the all of the rocaglates, 
sorted by structural class, are shown in Supplementary Table S1. These data were used to compare potencies of 
rocaglates as TRAIL sensitizers and as protein synthesis inhibitors and revealed a clear correlation (Fig. 3B). 
In general, the rocaglates were more potent as TRAIL sensitizers than as protein synthesis inhibitors under 
these experimental conditions (IC50s for protein synthesis inhibition averaged 4–5 x IC50s for TRAIL sensitiza-
tion). Since other protein synthesis inhibitors have been shown to sensitize various cells (including ACHNs) to 
TRAIL-induced apoptosis via down-regulation of cFLIP, a quantitative western blot assay was used to determine 
the effects of the rocaglates on protein expression of cFLIP. Figure 3C shows representative western blot analysis 
of cFLIP after ROC treatment. Quantitation of the long and short isoforms of cFLIP after treatment by ROC and 
the other TRAIL-sensitizing rocaglates showed general correlation between cFLIP protein levels and TRAIL sen-
sitization activity (Fig. 3D). The entire quantitative cFLIP expression data set for the active rocaglates is shown in 
Supplementary Figure S3. In general, the cFLIPS isoform appears to be more sensitive to rocaglates than the long 
form. ROC did not affect cFLIP mRNA levels (Supplementary Fig. S9).
Effects of rocaglates on other apoptotic targets. Changes in expression of some BCL-2 family mito-
chondrial proteins implicated in apoptosis have also been reported after ROC treatment. Other than a slight 
reduction in some cases after 24 h, BAK, BAX, BCL-2, BCL-XL, and BID levels were unchanged. Similarly, XIAP 
www.nature.com/scientificreports/
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levels were not affected except for a small decrease after 24 h. However, MCL-1 was diminished after treatment 
with ROC (Fig. 4A,B) or the four most active rocaglates (Fig. 4C).
ROC treatment leads to cell cycle arrest. All of the active rocaglates also inhibited cell growth by approx-
imately 50% as single agents at up to 10 µM (Supplemental Fig. S1). Given that the doubling time for ACHN cells 
under these experimental conditions is ~24 h, the rocaglate-induced growth inhibition was probably a cytostatic 
effect rather than cell death. ROC treatment resulted in cell cycle arrest at G2/M (Fig. 5). However, neither ROC 
nor 9 other rocaglates representing different structural classes (all < 50 nM IC50 for TRAIL sensitization) induced 
apoptosis (<2-fold increase in caspase 3 activity after up to 72 h treatment with 1 µM – Supplementary Fig. S2C).
Effects of rocaglates on other targets. ROC and other rocaglates have been reported to affect a number 
of cellular phenomena that have also been reported to affect sensitivity of cells to TRAIL. Among these are effects 
Figure 1. Sensitization of ACHN cells to TRAIL-induced apoptosis by rocaglamide. ACHN renal carcinoma 
cells (5000/well in 384-well plates) were treated for 4 h with or without various doses of rocaglamide followed 
by 18 h with or without TRAIL (40 ng/mL). (A) Cell survival was estimated by the XTT assay and normalized 
to untreated control wells. Error bars represent ± sd (n = 3 plates, duplicate wells per plate). *p < 0.001+/− 
TRAIL. (B) Cells were treated for 4 h with 100 nM rocaglamide followed by 2–18 h ± TRAIL and assessed for 
caspase 3 or caspase 8 activity. Error bars represent ± sd (n = 3) *p < 0.005 compared to control or TRAIL only. 
(C) Cells were pretreated for 2 h with or without 100 µM Z-VADFMK followed by 4 h ± rocaglamide (10 nM 
or 100 nM final concentration), then ± TRAIL for 18 h and assessment of cell survival by XTT. Error bars 
represent ± sd (n = 4). *p < 0.005 +/− TRAIL.
www.nature.com/scientificreports/
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on JNK and RAF-MEK-ERK signaling, ROS generation, and ER stress. Rapid activation by ROC of JNK (as meas-
ured by SP600125-sensitive JUN phosphorylation) and MEK/ERK signaling (as measured by UO126-sensitive 
increase in phosphoERK) was observed and the 4 most potent rocaglates had similar effects (Fig. 6). Neither total 
JUN nor total ERK levels were affected by any of the rocaglate treatments. Pretreatment with UO126 or with 
SP600125 did not alter either TRAIL-dependent or TRAIL-independent effects on cell numbers (Fig. 6 panels B 
and D). ROS generation was not detected (data not shown) and N-acetyl cysteine (NAC) pretreatment had no 
effect on cell numbers ± TRAIL. Supplementary Fig. S4 demonstrates that inhibition of MEK/ERK signaling, JNK 
signaling, or ROS generation by UO126, SP600125, and NAC respectively did not eliminate the TRAIL sensitiz-
ing effects of these or a selection of other rocaglates representing a range of structural classes. CHOP, an indicator 
of ER stress did not increase upon ROC treatment (data not shown). Levels of TRAIL receptor DR4, prohibitins, 
phosphoITCH, and eIF4E protein levels were also unaffected by ROC treatment and DR5 was slightly reduced. 
eIF4E phosphorylation was transiently increased, but substantially reduced by 24 h (Supplementary Fig. S5). 
Surface levels of TRAIL receptors were also analyzed by flow cytometry (Supplementary Fig. S6). DR4 levels did 
not change, nor did levels of cell surface “decoy” receptors (TR3 and TR4). Interestingly, however, unlike total 
DR5, surface DR5 expression appeared to increase with ROC treatment.
Effects of rocaglates on other renal cells. ROC and the four most potent analogs all sensitized CAKI-1 
and SN12C RCC cell lines to TRAIL-induced apoptosis in parallel with inhibition of protein synthesis in these 
cells (Fig. 7 and Supplementary Fig. S7). Relative potency of the 5 compounds followed that observed with ACHN 
cells for both measurements (Supplementary Fig. S7). Protein synthesis in human renal epithelial (HRE) cells was 
also affected at similar potencies, but HRE cells were considerably less susceptible to TRAIL sensitization (Figs 7 
and S8).
Discussion
A series of 29 structurally diverse rocaglates, including ROC, were identified as potent sensitizers of 
TRAIL-induced apoptosis in ACHN renal carcinoma cells. Pretreatment with these rocaglates primed the cells 
to respond to TRAIL. Protein synthesis inhibition by rocaglates resulted in rapid loss of cFLIP protein leading 
to enhanced death receptor signaling and subsequent caspase-dependent apoptotic cell death upon addition of 
TRAIL. Upregulation of TRAIL receptors is a common contributor to sensitization of cells to TRAIL-induced 
apoptosis and has been reported in response to ROC in other cell systems, but neither total DR4 nor DR5 were 
upregulated by ROC. Similarly, surface expression of “decoy” TRAIL receptors could contribute to TRAIL resist-
ance, but ROC did not affect these levels. However, cell surface DR5 did increase. Loss of cFLIP alone has been 
shown to sensitize ACHN cells to TRAIL16. Interestingly, the rocaglates were several fold more potent as TRAIL 
sensitizers as compared to protein synthesis inhibition (in parallel experiments under the same conditions) 
Figure 2. Structures of the highest potency rocaglates (IC50 values < 10 nM for TRAIL sensitization) and 
rocaglamide. Names in brackets correspond to names used elsewhere in the literature (see Discussion).
www.nature.com/scientificreports/
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suggesting that complete inhibition of cFLIP synthesis may not be necessary for TRAIL sensitization. cFLIP 
degradation is regulated by the JNK/ITCH pathway6 and JNK was activated by rocaglates, as has been previously 
reported in other cell systems21. JNK phosphorylates and activates ITCH, the ubiquitin ligase that controls cFLIP 
degradation6,33,34. However, ROC treatment did not affect levels of total or phospho-ITCH nor did inhibition of 
JNK affect TRAIL sensitization. cFLIP levels are regulated by transcription, translation, and degradation. Given 
that ROC did not affect cFLIP mRNA levels or ITCH activation, it is likely that the effects of the rocaglates on 
cFLIP are due to translation inhibition although other mechanisms cannot be entirely ruled out. These observa-
tions are consistent with the conclusion that inhibition of protein synthesis rather than increased proteasomal 
degradation probably results in rocaglate-induced loss of cFLIP proteins. Targets of translational inhibition by 
rocaglates are, in part, defined by their 5′ UTRs and this may lead to specific effects on cFLIP and potential cFLIP 
regulatory proteins22,24. Cross-talk between the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic 
pathways can result in diminished or amplified apoptotic signaling and the balance of pro- and anti-apoptotic 
mitochondrial proteins can significantly affect TRAIL-induced apoptosis35. In particular, XIAP overexpres-
sion can contribute to TRAIL resistance and increased expression of BAX and BAK can increase sensitivity to 
TRAIL. Other than MCL-1, however, the other mitochondrial proteins assessed did not change significantly 
by up to 8 h treatment with ROC and are thus probably not major contributors to predisposing ACHN cells to 
respond to subsequent treatment with TRAIL. After 24 h treatment with ROC, the result is more complicated in 
that there are both pro-apoptotic (BAK) and anti-apoptotic (BCL-2 and XIAP) proteins that were diminished 
whereas BID and BAX (pro-apoptotic) and BCL-XL (anti-apoptotic) were essentially unchanged. Investigation 
of rocaglate-induced interactions between the intrinsic and extrinsic pathways would be of interest in future 
studies as would possible cell type-specific effects (e.g. rocaglates as single agents did not induce apoptosis in 
ACHN cells). The rapid loss of MCL-1 protein upon rocaglate treatment may enhance the TRAIL-sensitization 
effect of the parallel loss of cFLIP protein. MCL-1 can cooperate in sensitization of cells to TRAIL35. However, as 
Figure 3. Inhibition of protein synthesis and cFLIP expression by rocaglates. (A) ACHN cells in 384-well 
black wall, clear bottom plates were treated with rocaglamide for 4 h (circles) or 24 h (squares) followed by 
labeling with puromycin (10 µg/mL final concentration for 30 min), fixation, and processing for ICW analysis of 
puromycylated protein (see Materials and Methods). (B) Correlation of protein synthesis inhibition with TRAIL 
sensitization for 29 rocaglates active as TRAIL sensitizers (i.e., <1000 nM IC50). Best fit line shown; slope: 0.86, 
correlation coefficient: 0.88. (C) ACHN cells were treated for 4 h or 24 h with 10, 100, or 1000 nM rocaglamide 
followed by analysis of cFLIP protein expression. (D) Effects of the 29 active rocaglates on cFLIP protein 
expression by ACHN cells were individually assessed by quantitative western blot analysis. Results were binned 
according to IC50 values for sensitization to TRAIL. cFLIP values (normalized to GAPDH and presented as % 
of untreated control values) were averaged for all compounds in each bin. Cells were treated 4 h with rocaglates 
alone at 10 nM, 100 nM, or 1000 nM. Error bars represent sem, n = 4–13. See Supplementary Table S1 for 
protein synthesis inhibition, Supplementary Figure S3 for cFLIP expression data for individual rocaglates and 
Supplementary Fig. S10 for full-length cFLIP/rocaglamide blot. *p < 0.05, **p < 0.001 compared to untreated 
control.
www.nature.com/scientificreports/
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seen with other RCC cell lines36, knockdown of MCL-1 with siRNA did not sensitize ACHN cells to TRAIL (data 
not shown) suggesting that loss of MCL-1 may play only a minor role, if any, in sensitization of ACHN cells to 
TRAIL by rocaglates. Increased cell surface expression of DR5, on the other hand, may contribute to increased 
TRAIL signaling.
Induction of cell cycle arrest by ROC and analogs has been reported to occur at G1/G0 or at G2/M (with 
insignificant cell death) depending on the cells investigated21,24,37. In this study with ACHN cells, treatment with 
ROC alone led to G2/M cell cycle arrest without subsequent apoptotic cell death. Reported effects of rocaglates 
on RAF-MEK-ERK signaling have also been cell-type-specific. RAF-MEK-ERK signaling has often been 
reported to be inhibited (often involving prohibitin) leading to CDC25A degradation and G1 cell cycle arrest 
and loss of eIF4E phosphorylation21, but sometimes reported to be increased. For example, in Jurkat cells ERK 
Figure 4. Rocaglates affect expression of MCL-1. (A) ACHN cells were treated with rocaglamide for 1–24 h 
followed by western blot analysis of indicated pro- and anti-apoptotic proteins. (B) Quantitative western blot 
analysis of ROC-treated cells. *p < 0.05 compared to untreated control. (C) Quantitative western blot analysis 
of MCL-1 protein assessed after 4 h treatment with the indicated rocaglate. Quantitative values were normalized 
to loading control (GAPDH) and expressed as a % of signal for untreated cells run on the same gel. MCL-1/
GAPDH ratios shown in Supplementary Fig. S10. Cropped blot images are shown – see Supplementary Fig. S10 
for full-length blots.
Figure 5. Rocaglamide treatment leads to cell cycle arrest. ACHN cells were treated with 1000 nM rocaglamide 
for the indicated times followed by flow cytometry analysis of cell cycle. Error bars represent sd. *p < 0.05 for 
accumulation compared to control.
www.nature.com/scientificreports/
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phosphorylation was inhibited by ROC and analogs while ERK phosphorylation was significantly increased in 
NIH/3T3 cells under the same conditions38. Although ERK activation typically drives cell cycle progression, it 
can result in G2/M arrest39,40. However, given that ERK activation was transient and inhibition affected neither 
the cytostatic effects of rocaglates nor their TRAIL sensitization effects, the functional significance of enhanced 
RAF-MEK-ERK signaling in ROC-treated ACHN cells is uncertain. Similarly, eIF4E phosphorylation, which 
results from RAF-MEK-ERK pathway activation21,22,38, was transiently increased by rocaglamide treatment (peak-
ing at 4–8 h) followed by reduction to less than control levels by 24 h. However, translation inhibition was per-
sistent from 4–24 h as were reductions in the levels of cFLIP and MCL-1. These results are consistent with the 
previous conclusion that inhibition of translation by rocaglates is independent of eIF4E phosphorylation38.
Figure 6. Effects of rocaglates on JNK and MEK/ERK signaling. ACHN cells were treated with rocaglamide 
for 1–24 h, or the indicated rocaglate for 4 h followed by western blot analysis. In parallel, prior to rocaglamide 
addition, cells were pre-incubated for 1 h with the indicated kinase inhibitor. (A) phosphoJUN, (C) 
phosphoERK. For panels B (JNK inhibitor) and D (MEK inhibitor), cells were pretreated for 1 h with or without 
inhibitor as indicated followed by rocaglate (100 nM) for 4 h, then with (black bars) or without (open bars) 
TRAIL overnight followed by XTT assay (cell numbers were normalized to untreated wells and shown as % of 
untreated control ± sd). Statistical significance: *p < 0.01 (TRAIL+ vs TRAIL− pairs), **p < 0.01 (SP600125− 
vs. SP600125+), xp < 0.01 (rocaglate− vs. rocaglate+). Cropped blot images are shown – see Supplementary 
Fig. S10 for full-length blots.
Figure 7. Effects of rocaglates on CAKI-1, SN12C, and HRE. Renal carcinoma or HRE cells (5000/well in 384-
well plates) were treated for 4 h with or without the indicated rocaglate followed by 18 h with or without TRAIL 
(40 ng/mL). Cell survival was estimated by the XTT assay and normalized to untreated control wells. Error bars 
represent ± sd (n = 4). *p < 0.01 (TRAIL+ vs. TRAIL− pairs). Complete dose-response curves are shown in 
Supplementary Figs S7 and S8.
www.nature.com/scientificreports/
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Four of the rocaglates, three of which were hydroxamates, were considerably more potent than ROC itself 
(<10 nM) and one compound (SDS-1–021) had sub-nM potency as a TRAIL sensitizer (see Supplementary 
Table S1). A number of the compounds assessed in this work have previously been investigated in other cell 
systems. In particular, hydroxamates27 such as SDS-1-021 (CMLD010509), (−)-RHT (CMLD010515), and 
CR-1–31B (CMLD005522) have been used in a variety of applications38,41–44. In previous studies, SDS-1-021 was 
typically the most potent of the rocaglates investigated as also found here. For example, Chu, and coworkers38 
found it to be more potent than ROC which was in turn more potent than CR-1-31B in Jurkat cells (CR-1-31B 
and SDS1-021 were equipotent in NIH-3T3 cells) with low nM IC50s. In the present study, in general, substituting 
hydroxamates for the amide of ROC maintains or enhances potency while conversion to ester decreases potency 
(e.g., compare ROC to CMLD010852). Other isosteric substitutions for the amide or its elimination were gener-
ally well-tolerated (e.g., compare ROC to CMLD010536 or to (±)-rocaglaol). Substitution of the methoxy group 
on ring B of the molecule (nomenclature per Pan, and coworkers22) significantly increases potency (e.g., compare 
CR-1-31B with SDS-1-021). As seen with ACHN cells in the present report, exo-RHT (CMLD010441), unlike the 
bioactive endo stereoisomer (−)-RHT, is a poor protein synthesis inhibitor28. In fact, all exo diasteroisomers of 
active compounds that were tested were either inactive or had very low (>0.5 µM) activity with TRAIL sensitiza-
tion and >1 µM for protein synthesis inhibition (see Supplementary Table S1). The tested aglains and rocaglate 
β-lactones were inactive.
Although the rocaglates were generally more potent as TRAIL sensitizers than as protein synthesis inhibi-
tors, there were a few exceptions (Supplementary Table S1). In particular, three compounds in the oxazinone/
pyridazone ring system class (CMLD010535, 506, and 483) and one with a monofluorinated phloroglucionol 
ring (CMLD010337) were roughly equipotent. The one thiazole ketone tested (CMLD005551) was slightly more 
potent as a protein synthesis inhibitor, although it was one of the least potent of the active compounds. These 
outliers may suggest possible alternative targets in addition to protein synthesis inhibition that may merit further 
investigation.
Rocaglamide and its analogs have been extensively investigated. As a result, a significant amount is known 
about their general cell biological and biochemical effects. In particular with regard to TRAIL, there are a number 
of reported effects of rocaglates that have also (in other contexts) been demonstrated to be able to sensitize cells 
to TRAIL. Among these are ROS generation, MEK/ERK signaling, JNK signaling (including ITCH effects), death 
receptor expression levels, activation of the intrinsic mitochondrial pathway, ER stress, cell cycle arrest. All of 
these effects have been addressed in the present work conclusively ruling out a large number of otherwise plausi-
ble mechanisms. This leads inevitably to the conclusion that protein synthesis inhibition leading to loss of cFLIP, 
potentially augmented by loss of MCL-1 and increased cell surface DR5, result in sensitization of TRAIL-resistant 
RCC cells to TRAIL-induced apoptosis.
ROC and analogs continue to be pursued as stand-alone anti-cancer agents. In particular, rocaglates are being 
investigated as potential therapeutics for a variety of cancer types including leukemias, melanomas, myelomas, 
lung cancer, breast cancer, colon cancer, prostate cancer and glioblastoma due to their multiple mechanisms of 
action; induction of apoptosis via protein synthesis inhibition, modulation of signaling pathways, cell cycle regu-
lation, etc.21,23. The results reported here suggest expansion of these potential applications to include combination 
therapies (with TRAIL) for RCC as well as providing additional insights into their actions and structure-activity 
relationships. Although beyond the scope of this investigation, these results also illustrate a clear need to develop 
contextual understanding of the effects of rocaglates on various signaling pathways and the consequences of those 
effects in cellular context. As has been seen in the past, there are important differences and similarities both in 
regard to TRAIL sensitization mechanisms and effects as stand-alone reagents depending on the cellular environ-
ment of the study which will be important future investigative pathways.
Materials and Methods
Chemicals and reagents. 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbon-
yl]-2H-tetrazolium hydroxide (XTT; NSC 601519) was obtained from the NCI Drug Synthesis and Chemistry 
Branch. Sources of other reagents included: recombinant TRAIL ligand (168 amino acid TNF homologous 
extracellular domain – Peprotech, Rocky Hill, NJ); Z-VAD-FMK (Promega, Madison, WI); cell culture media 
and additives (Cellgro, Hyclone, Sigma, or Invitrogen); BCA protein assay kits (Pierce/Thermo); puromycin 
(Invitrogen, Carlsbad, CA). Monoclonal mouse anti-puromycin clone 12D10 and rabbit anti-GAPDH (ABS16) 
were obtained from EMD-Millipore (Billerica, MA). Secondary antibodies: Goat anti-rabbit (800) and Goat anti-
mouse (680) and blocking buffer were from LiCor (Lincoln, NE). Other reagents from Sigma (St. Louis, MO).
Sources of rocaglates. ROC (NSC326408) and didesmethyl rocaglamide (NSC705956) were provided by 
the National Cancer Institute (Frederick, MD). The remaining rocaglates were from the Boston University Center 
for Molecular Discovery (BU-CMD) compound collection.
Cell growth and apoptotic signaling assays. ACHN, CAKI-1, and SN12C cells (NCI) were main-
tained and growth was assayed as described11,13. Human renal epithelial (HRE) cells were purchased from Lonza 
(Walkersville, MD) and maintained according to the company’s recommendations. For TRAIL sensitization 
assays, cells were allowed to attach overnight (3500–5000 cells/well, 384-well plates) followed by 4 h with com-
pounds or DMSO. TRAIL (40 ng/ml final) was added and cell numbers were estimated (18–24 h) using XTT. 
For analysis of reactive oxidative species (ROS) involvement, N-acetyl cysteine (NAC, 10 mM) was added just 
before compounds and remained in the plates throughout. NAC interference with the XTT assay was previously 
observed12, so cell numbers were estimated by measuring total cell protein using Sulforhodamine B11. For caspase 
inhibition, cells were pretreated with 100 µM ZVAD-FMK. For assessment of caspase activation, cells were treated 
for 4 h followed by TRAIL (1–24 h). For assessment of caspase 3 activation in the absence of TRAIL, cells were 
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treated with rocaglate for up to 72 h. Assessment of caspase 8 or 3 utilized Caspase-GloTM 8 or 3/7 assay kits 
(Promega) according to manufacturer’s instructions. The use of these kits for evaluation of caspase activation has 
been previously validated for ACHN cells11–13.
Quantitation of protein synthesis. Protein synthesis was assessed by measuring incorporation of 
puromycin to quantitate nascent polypeptides in an InCell western (ICW) format as described20. Briefly, cells 
plated in black-wall, clear-bottom, polylysine-coated plates were treated with indicated compounds followed by 
pulse-labeling with puromycin (10 µg/mL for the final 30 min of the treatment). After formaldehyde fixation, per-
meabilization (0.1% Triton X-100 (v:v) in PBS), extensive washing, and blocking (LiCor blocking buffer), mouse 
anti-puromycin and rabbit anti-GAPDH were mixed and added. Secondary antibodies were goat anti-mouse 
(680) and goat anti-rabbit (800) (from LiCor) to detect puromycin and GAPDH respectively. For quantitation, 
plates were scanned on the LiCor Odyssey instrument in “InCellWestern” mode capturing relative fluorescence 
in each channel.
Immunoblot. Cells (2 × 106 cells/well, 6-well plates) were treated and extracted for SDS-PAGE and immu-
noblot analysis. The following primary antibodies were used: Monoclonal mouse anti-cFLIP clone 7F10 was 
obtained from Enzo (Farmingdale, NY). Polyclonal rabbit anti-MCL-1, anti-BCL- xL, anti-BCL-2, anti-BID, 
anti-Bak, anti-Bax, polyclonal rabbit anti-c-JUN, anti-phospho-c-JUN (Ser 63) II, anti-p44/42 MAPK (Erk1/2), 
monoclonal rabbit anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) clone 197G2, anti-DR4 clone D9S1R, 
anti-DR5 clone D4E9, polyclonal rabbit anti-eIF4E and anti-phospho eIF4E (Ser209) were obtained from Cell 
Signaling Technologies (Beverly, MA). Polyclonal rabbit anti-prohibitin was obtained from Abcam (Cambridge, 
MA). Primary antibodies for target proteins and loading control (GAPDH) were paired such that one was murine 
and the other rabbit. Detection employed secondary antibodies labeled with near IR fluorophores (same as in 
ICW). Blots were scanned using the LiCor Odyssey scanner and each channel simultaneously visualized and 
quantitated using the instrument software20. Cropped gray-scale images of blots are shown in the main text fig-
ures while full-length color images are shown in Supplementary Information for all of the blots from which the 
figures were derived.
Cell cycle analysis. ACHN renal carcinoma cells (1.5 × 106/well in 6-well plates) were treated with DMSO 
(control) or ROC (1000 nM) and incubated for 4, 8 or 18 h. After incubation, the cells were collected by trypsin-
ization and fixed in 100% ice cold methanol for 15 minutes. Fixed cells were decanted and washed with PBS, 
resuspended in 150 μL of Propidium Iodide staining solution (containing propidium iodide, RNase and PBS) and 
then incubated at 37 °C for 40 minutes. Stained cells were collected by centrifugation, washed and resuspended 
in 200 μL PBS, and visualized using Cellometer Vision CBA image cytometer. Stained cells were analyzed for cell 
cycle distribution using Vision CBA and FCS Express Software. Results were binned per cell population in differ-
ent phases of cell cycle (represented as % of total cell population).
Data analysis and presentation. Unless otherwise noted, all results were normalized to control 
(DMSO)-treated cells and quantitation reported as average ± standard deviation. Statistical significance of cell 
survival in the presence vs. absence of TRAIL was assessed by t-test (p < 0.05 considered significant). IC50 values 
were estimated from dose-response curves using SigmaPlot 4-parameter logistic nonlinear regression analysis 
(SPSS, Inc.). Quantitation of western blot data and ICW (i.e., puromycylation) data included normalization of 
signals to GAPDH.
Data Availability
The data contributing to this study are included in the manuscript and/or Supplementary Information.
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